| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Heng Wu, Jing Wei, Xiumiao Zhao, Ying Liu, Zhihang Chen, Kehong Wei, Jiachen Lu, Wenjie Chen, Meixiu Jiang, Shengjie Li, Tingtao Che. Neuroprotective effects of an engineered Bioengineering & translational medicine. vol 8. issue 5. 2023-09-11. PMID:37693045. |
neuroprotective effects of an engineered considerable evidence suggests that insulin resistance is closely linked to parkinson's disease (pd), leading to agents aiming at treating diabetes can be regarded as new neuroprotective strategies in pd, notably glucagon-like peptide-1 (glp-1). |
2023-09-11 |
2023-10-07 |
Not clear |
| I N Tyurenkov, T I Faibisovich, D A Bakuli. [Synergistic effects of GABA and hypoglycemic drugs]. Problemy endokrinologii. vol 69. issue 4. 2023-09-11. PMID:37694868. |
it has been established that in animals with dm, gaba suppresses apoptosis and stimulates the regeneration of β-cells, increases β-cell mass and insulin production.experimental data have been obtained indicating a synergistic effect of gaba when combined with glucagon-like peptide-1 (glp-1) receptor agonists, dpp-4 inhibitors and sodium-glucose cotransporter 2 (sglt-2) inhibitors, when a more pronounced pancreoprotective effect is observed, due to decrease in oxidative and nitrosative stress, inflammation, increase in the level of klotho protein, nrf-2 activity and antioxidant defense enzymes, suppression of nf-kb activity and expression of pro-inflammatory cytokines. |
2023-09-11 |
2023-10-07 |
Not clear |
| I N Tyurenkov, T I Faibisovich, D A Bakuli. [Synergistic effects of GABA and hypoglycemic drugs]. Problemy endokrinologii. vol 69. issue 4. 2023-09-11. PMID:37694868. |
as a result, all this leads to a decrease in apoptosis and death of β-cells, an increase in β-cell mass, insulin production and, at the same time, a decrease in glucagon levels and insulin resistance.the review substantiates the feasibility of using gaba and drugs with a positive gabaeric effect in combination with new generation antidiabetic agents: glp-1 receptor agonists, dpp-4 inhibitors and sglt-2 inhibitors in order to increase their antidiabetic potential.the search was carried out in the databases pubmed, elibrary, medline. |
2023-09-11 |
2023-10-07 |
Not clear |
| Riccardo Candido, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Raffaele Napol. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023-09-07. PMID:37679243. |
to assess intensification approaches with basal insulin (bi) following glucagon-like peptide-1 receptor agonist (glp-1 ra) treatment in type 2 diabetes (t2d). |
2023-09-07 |
2023-10-07 |
Not clear |
| Jennifer Leohr, Maria C Kjellsso. Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1. CPT: pharmacometrics & systems pharmacology. 2023-09-05. PMID:37667531. |
evaluation of postprandial total triglycerides within the tigg model for characterizing postprandial response of glucose, insulin, and glp-1. |
2023-09-05 |
2023-09-07 |
Not clear |
| Jennifer Leohr, Maria C Kjellsso. Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1. CPT: pharmacometrics & systems pharmacology. 2023-09-05. PMID:37667531. |
the two models were compared on their predictability to characterize the postprandial response of glucose, insulin, and active glp-1. |
2023-09-05 |
2023-09-07 |
Not clear |
| Marine Monney, François R Jornayvaz, Karim Garian. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes & metabolism. 2023-09-01. PMID:37657738. |
glp-1 receptor agonist has a peripheral and a central action, including stimulation of glucose-dependent insulin secretion and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food intake. |
2023-09-01 |
2023-09-07 |
Not clear |
| Peyman Rezaie, Vida Bitarafan, Braden David Rose, Kylie Lange, Zinat Mohammadpour, Jens Frederik Rehfeld, Michael Horowitz, Christine Feinle-Bisse. Effects of Quinine on the Glycaemic Response to, and Gastric Emptying of, a Mixed-Nutrient Drink in Females and Males. Nutrients. vol 15. issue 16. 2023-08-26. PMID:37630774. |
intraduodenal quinine, in the dose of 600 mg, stimulates glucagon-like peptide-1 (glp-1), cholecystokinin and insulin; slows gastric emptying (ge); and lowers post-meal glucose in men. |
2023-08-26 |
2023-09-07 |
human |
| Marisa Jadna Silva Frederico, Andreza Cipriani, Jocelyn Brice Alexandre Heim, Ana Karla Bittencourt Mendes, Marcela Aragón, Joana Margarida Gaspar, Nylane Maria Nunes De Alencar, Fátima Regina Mena Barreto Silv. Electrophilic Agonists Modulate the Transient Receptor Potential Ankyrin-1 Channels Mediated by Insulin and Glucagon-like Peptide-1 Secretion for Glucose Homeostasis. Pharmaceuticals (Basel, Switzerland). vol 16. issue 8. 2023-08-26. PMID:37631083. |
electrophilic agonists, cin and aitc, inhibited disaccharidases and acted as secretagogues in the intestine by inducing glp-1 release in vivo and in vitro and contributed to insulin secretion and glycemia. |
2023-08-26 |
2023-09-07 |
rat |
| Pamela Bowman, Kashyap A Patel, Timothy J McDonald, Jens J Holst, Bolette Hartmann, Maria Leveridge, Beverley M Shields, Suzie Hammersley, Steve R Spaull, Bridget A Knight, Sarah E Flanagan, Maggie H Shepherd, Rob C Andrews, Andrew T Hattersle. Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea-treated KCNJ11 neonatal diabetes. Journal of diabetes investigation. 2023-08-21. PMID:37602910. |
the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), are thought to be the main drivers of insulin secretion in individuals with sulfonylurea (su)-treated kcnj11 permanent neonatal diabetes. |
2023-08-21 |
2023-09-07 |
human |
| Frans Schuit, Jonathan E Campbel. GPCR Promiscuity Reshapes Islet Physiology. Diabetes. vol 72. issue 9. 2023-08-21. PMID:37603722. |
glp-1 is described as a postprandial hormone that stimulates anabolic actions via insulin, while glucagon is viewed as a fasting hormone that drives catabolic actions to maintain euglycemia. |
2023-08-21 |
2023-09-07 |
Not clear |
| Mingkai Zhang, Ling Zhu, Hui Zhang, Xingguo Wang, Gangcheng Wu, Xiguang Q. Transepithelial Transport of the Bifunctional Peptide IPYWTY Indirectly Induced Insulin Release Mediated by Active GLP-1. Journal of agricultural and food chemistry. 2023-08-17. PMID:37587911. |
transepithelial transport of the bifunctional peptide ipywty indirectly induced insulin release mediated by active glp-1. |
2023-08-17 |
2023-09-07 |
Not clear |
| Colleen Gavigan, Thomas Donne. Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes. Journal of diabetes research. vol 2023. 2023-08-17. PMID:37589043. |
physicians lack guidance as to which patients with insulin-requiring type 2 diabetes will respond best to glp-1 ras with respect to glycemic control, insulin dose reduction, and weight loss. |
2023-08-17 |
2023-09-07 |
Not clear |
| Colleen Gavigan, Thomas Donne. Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes. Journal of diabetes research. vol 2023. 2023-08-17. PMID:37589043. |
this study evaluated the efficacy of glp-1 ras in patients with type 2 diabetes on insulin and patient factors that may predict a beneficial clinical response. |
2023-08-17 |
2023-09-07 |
Not clear |
| Gary E Aspnes, Scott W Bagley, Steven B Coffey, Edward L Conn, John M Curto, David J Edmonds, Julien Genovino, David A Griffith, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M Mathiowetz, David W Piotrowski, Colin R Rose, Roger B Ruggeri, Liuqing We. 6-Azaspiro[2.5]octanes as Small Molecule Agonists of the Human Glucagon-Like Peptide-1 Receptor. Bioorganic & medicinal chemistry letters. 2023-08-17. PMID:37591316. |
activation of the glucagon-like peptide-1 (glp-1) receptor stimulates insulin release, lowers plasma glucose levels, delays gastric emptying, increases satiety, suppresses food intake, and affords weight loss in humans. |
2023-08-17 |
2023-09-07 |
human |
| Philip N Newsome, Phil Amber. Incretins (GLP1 r agonists and dual, triple agonists) and the liver. Journal of hepatology. 2023-08-10. PMID:37562748. |
there remains debate as to whether glp-1 receptor agonists have direct, independent effects to improve mash or whether they impact on pathophysiology through improvements in weight, insulin resistance and glycaemic control. |
2023-08-10 |
2023-08-16 |
Not clear |
| Chantal Mathieu, Iraj Ahmadza. Incretins beyond type 2 diabetes. Diabetologia. 2023-08-08. PMID:37552238. |
in type 1 diabetes, the addition of glp-1 receptor agonists to intensive insulin therapy lowers weight and required insulin doses compared with placebo, but the effects on glucose control (hba |
2023-08-08 |
2023-08-14 |
Not clear |
| Stine Smedegaard, Ulla Kampmann, Per G Ovesen, Henrik Støvring, Nikolaj Ritti. Whey Protein Premeal Lowers Postprandial Glucose Concentrations in Adults Compared with Water-The Effect of Timing, Dose, and Metabolic Status: a Systematic Review and Meta-analysis. The American journal of clinical nutrition. vol 118. issue 2. 2023-08-03. PMID:37536867. |
the underlying mechanisms are only partly understood but may involve stimulation of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic polypeptide (gip), and insulin secretion together with a slower gastric emptying rate. |
2023-08-03 |
2023-08-14 |
Not clear |
| Marah Alsayed Hasan, Stanley Schwartz, Victoria McKenna, Richard In. An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review. Obesity surgery. 2023-08-02. PMID:37530920. |
after bariatric surgery, significant changes are seen in insulin sensitivity, beta cell function, glucagon-like peptide 1 (glp-1) levels, the gut microbiome, and bile acid metabolism. |
2023-08-02 |
2023-08-14 |
Not clear |
| Michelantonio De Fano, Francesca Porcellati, Carmine G Fanelli, Sofia Corio, Alessio Mazzieri, Paola Lucidi, Geremia B Bolli, Gabrio Bassott. THE ROLE OF GASTRIC EMPTYING IN GLUCOSE HOMEOSTASIS AND DEFENSE AGAINST HYPOGLYCEMIA: INNOCENT BYSTANDER OR PARTNER IN CRIME? Diabetes research and clinical practice. 2023-07-22. PMID:37481116. |
recent guidelines recommend glp-1 receptor agonists (glp-1ras) either as the first injectable therapy for type 2 diabetes mellitus or in combination with insulin. |
2023-07-22 |
2023-08-14 |
human |